Abstract
This study aimed to evaluate the systemic effect of strontium ranelate (SR) on peri-implant bone tissue. Thirty-six adult rats were divided into three experimental groups: sham (SHAM), ovariectomized (OVX) and ovariectomized rats treated with strontium ranelate (OVX-Sr). Strontium ranelate (625mg/kg) was administered by oral gavage on a daily basis. The implants were installed on the tibiae. The euthanasia occurred 42 and 60 days after the implants were installed, and the biomechanical (reverse torque); PCR-RT; histological; immunohistochemical; confocal microscopy and histometric analysis were performed. Quantitative data was subjected to statistical tests with significance level set at p<0.05. Significant increase in implant reverse torque in OVX-Sr was observed when compared to OVX. PCR analysis showed an increase in the genetic expression of the proteins responsible for bone formation in OVX-SR. In the histological analysis, SHAM and OVX-Sr showed a higher degree of maturation of peri-implant bone tissue. Ran-Sr presented higher immunolabeling for ALP and OPN proteins when compared to OVX. In the confocal microscopy, OVX-Sr there was good bone neoformation showed by incorporation of Alizarin red fluorochrome. The histometric analysis, bone implant contact (BIC) and neoformed bone area (NBA) presented statistically difference among all groups, and the Ran-Sr presented the highest BIC. Thus, strontium ranelate improves osseointegration and quality of neoformed bone tissue around implants in estrogen deficient rats.
Highlights
Osteoporosis is the principal systemic skeletal disease characterized by decreased bone density and a deterioration in bone quality (Compston et al 2019; Cosman et al 2014), can be classified primarily as juvenile, postmenopausal, and senile osteoporosis and secondarily is related to several diseases, such as endocrine, hematological, rheumatic, gastrointestinal, or from medications such as glucocorticoids (Tarantino et al 2017)
This study aimed to evaluate the systemic effect of strontium ranelate (SR) on peri-implant bone tissue
The set of results shows that systemic strontium ranelate was effective in improving several parameters related to osseointegration and evaluation of peri-implant bone tissue
Summary
Osteoporosis is the principal systemic skeletal disease characterized by decreased bone density and a deterioration in bone quality (Compston et al 2019; Cosman et al 2014), can be classified primarily as juvenile, postmenopausal, and senile osteoporosis and secondarily is related to several diseases, such as endocrine, hematological, rheumatic, gastrointestinal, or from medications such as glucocorticoids (Tarantino et al 2017). Besides the good action in bone tissue (Grynpas at al. 1990), with reduction on vertebral and non-vertebral fracture in postmenopausal women (Meunier et al 2004; Reginster et al 2005), RE is strongly related to skin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
